TAK — Takeda Pharmaceutical Share News
0.000.00%
Last trade - 00:00- $66.14bn
- $92.15bn
- ¥5tn
Takeda's immune disease drug meets main goal of mid-to-late stage trial
Brief: Takeda Announces Positive Topline Results From Pivotal Phase 2/3 Clinical Trial Of Tak-881 In Primary Immunodeficiency Disease (Pid)
Factbox: Pharma sector doubles down on AI amid hopes of slashing costs, timelines
Spyre's inflammatory bowel drug shown to reduce disease activity in mid-stage study (updated)
Spyre's inflammatory bowel drug reduces disease activity in mid-stage study
Denali slips as Takeda exits dementia drug partnership
Axsome rises as it buys rights to experimental schizophrenia drug
Takeda's psoriasis pill succeeds in late-stage studies
Takeda Announces Next Steps In Its Transformation To Strengthen Competitiveness And Accelerate Future Growth Outlook
Brief: Alan Walshe Appointed General Manager Of Takeda Canada
Takeda Announces U.S. FDA Accepts NDA And Grants Priority Review For Rusfertide As A Potential First-In-Class Therapy For Polycythemia Vera
Novo Nordisk nominates Jan van de Winkel and Ramona Sequeira to board (updated)
Brief: Takeda's ENTYVIO Shows Promise For Treating Ulcerative Colitis In Children
U.S. FDA Accepts NDA And Grants Priority Review For Takeda's Oveporexton (Tak-861) As A Potential First-In-Class Therapy For Narcolepy Type 1
Brief: Iambic Announces Collaboration With Takeda To Advance AI-Driven Design Of Small Molecules
Takeda deepens AI drug discovery push with $1.7 billion Iambic deal
Table: Takeda Pharma -9-MTH group results (IFRS)
U.S. drugmakers slip as 2028 Medicare price list adds 15 medicines
Brief: CMS Announces Selection Of Drugs For Third Cycle Of The Medicare Drug Price Negotiation Program